A key finding in our study is that FAK remains a relevant target in fully BRAFi-resistant melanoma cells driven by Rac1 activation, lending important additional support to idea that targeting FAK signaling may have utility in a variety of therapy-resistant melanomas, as recently proposed by Lubrano et al. [34]. This evidence concerns the gene RAC1 and melanoma.